Adding Daratumumab to Bortezomib, Dex Prolongs PFS in Multiple Myeloma

Share this content:
Adding daratumumab to bortezomib and dexamethasone prolonged progression-free survival in relapsed or relapsed and refractory multiple myeloma.
Adding daratumumab to bortezomib and dexamethasone prolonged progression-free survival in relapsed or relapsed and refractory multiple myeloma.

Adding daratumumab to bortezomib and dexamethasone prolonged progression-free survival, in contrast with bortezomib and dexamethasone alone, for patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in The New England Journal of Medicine.1

For this phase 3 trial, investigators enrolled 498 patients with relapsed or relapsed and refractory multiple myeloma and randomly assigned them to receive bortezomib and dexamethasone alone or with daratumumab.

The 12-month progression-free survival rate was 60.7% in the daratumumab group, in contrast with 26.9% in the control arm.

With a median follow-up of 7.4 months, median progression-free survival was not reach for daratumumab-treated patients, and was 7.2 months in the bortezomib and dexamethasone alone group, corresponding to a 61% reduction in the risk of progression or death with daratumumab (hazard ratio, 0.39; 95% CI, 0.28-0.53; P < .001).

RELATED: Multiple Myeloma: Finding Resources and Support

The overall response rate was also higher in daratumumab arm versus the control arm (82.9% versus 63.2%; P < .001), as were the rates of complete response or better (P = .001) and very good partial response or better (P = .001).

Infusion-related reactions were reported among 45.3% of patients treated with daratumumab, with most being grade 1 or 2, and occurring during the first infusion.               

Reference

  1. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:754-766.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters